- Home
- GMRE vs SVRA Comparison
GMRE vs SVRA Comparison
Compare GMRE & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMRE
- SVRA
- Stock Information
- Founded
- GMRE 2011
- SVRA 2007
- Country
- GMRE United States
- SVRA United States
- Employees
- GMRE N/A
- SVRA N/A
- Industry
- GMRE Real Estate Investment Trusts
- SVRA Biotechnology: Pharmaceutical Preparations
- Sector
- GMRE Real Estate
- SVRA Health Care
- Exchange
- GMRE Nasdaq
- SVRA Nasdaq
- Market Cap
- GMRE 485.5M
- SVRA 505.8M
- IPO Year
- GMRE N/A
- SVRA N/A
- Fundamental
- Price
- GMRE $6.82
- SVRA $2.92
- Analyst Decision
- GMRE Buy
- SVRA Buy
- Analyst Count
- GMRE 4
- SVRA 6
- Target Price
- GMRE $10.25
- SVRA $8.83
- AVG Volume (30 Days)
- GMRE 466.3K
- SVRA 598.8K
- Earning Date
- GMRE 05-07-2025
- SVRA 05-16-2025
- Dividend Yield
- GMRE 12.29%
- SVRA N/A
- EPS Growth
- GMRE N/A
- SVRA N/A
- EPS
- GMRE 0.03
- SVRA N/A
- Revenue
- GMRE $138,300,000.00
- SVRA N/A
- Revenue This Year
- GMRE $7.29
- SVRA N/A
- Revenue Next Year
- GMRE $3.71
- SVRA N/A
- P/E Ratio
- GMRE $209.53
- SVRA N/A
- Revenue Growth
- GMRE N/A
- SVRA N/A
- 52 Week Low
- GMRE $6.75
- SVRA $2.26
- 52 Week High
- GMRE $10.46
- SVRA $5.31
- Technical
- Relative Strength Index (RSI)
- GMRE 28.48
- SVRA 56.79
- Support Level
- GMRE $7.63
- SVRA $2.81
- Resistance Level
- GMRE $7.81
- SVRA $3.56
- Average True Range (ATR)
- GMRE 0.22
- SVRA 0.18
- MACD
- GMRE -0.04
- SVRA -0.01
- Stochastic Oscillator
- GMRE 3.54
- SVRA 57.77
About GMRE Global Medical REIT Inc.
Global Medical REIT Inc is engaged predominantly in the acquisition of purpose-built healthcare facilities and the leasing of those facilities to physician groups and regional and national healthcare systems. The company's principal business objective is to provide attractive, risk-adjusted returns to its stockholders through a combination of reliable dividends and long-term capital appreciation. Its healthcare facilities are located in secondary markets and suburbs of primary markets and are typically leased to single-tenants under triple-net leases.
About SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.